.png){kind=icon}
.png){kind=icon}
Return
Allogeneic CAR-T cell therapy in autoimmune diseases
.png){kind=icon}
PRE
AI
Y
J
杜
DOI：10.1080/1750743X.2025.2572963.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Emerging evidence demonstrates the potential efficacy of chimeric antigen receptor (CAR) T cells in autoimmune diseases. Currently, this therapy relies primarily on patient-derived autologous CAR-T cells. However, the application of autologous CAR-T cells is hindered by several limitations, such as high costs, time-consuming, and vulnerability to failure during the manufacturing process. Allogeneic CAR-T cells are genetically engineered T cells derived from healthy donors that hold great promise for expanding the accessibility of CAR-T cell therapy and may overcome the limitations of autologous CAR-T cells. Recent studies with small sample sizes have suggested the potential of allogeneic CAR-T cells in autoimmune diseases. These results have motivated researchers and physicians to further investigate the application of allogeneic CAR-T cells. In this review, we discuss the development of allogeneic CAR-T cells, current studies on CAR-T cell therapy for autoimmune diseases, and potential toxicities of allogeneic CAR-T cells. In addition, we discuss current challenges and future directions for implementing this therapy in clinical practice.
Keywords:
Allogeneic CAR-T
Autoimmune disease
GVHD
HVGR
CRS
ICANS
Lymphodepleting chemotherapy
Journal
J
IF:
2.9
Papers:
2.1K
Citations:
3.2K
Organization
Cited Papers